Skip to content

US · ANIX · BIOTECHNOLOGY

Anixa Biosciences, Inc. (ANIX) intrinsic value and stock valuation

$2.44as of 2026-11-21 · Mkt cap 116.02M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Anixa Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values ANIX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ANIX’s statements →

Anixa Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Jose, CA 95118 anixa.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-10.93M
20112025
Free cash flow
-$-7.17M
20112025
Total equity
$14M+11.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$210K$0.00$510K
Operating income-$-11.7M-$-13.83M-$-11.01M-$-13.88M-$-13.14M
Net income-$-10.93M-$-12.55M-$-9.81M-$-13.6M-$-12.95M
EPSd-$-336.83K-$-393.42K-$-316.66K-$-447.81K-$-453.11K
Operating cash flow-$-7.17M-$-7.33M-$-6.21M-$-6.49M-$-4.94M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-7.17M-$-7.33M-$-6.21M-$-6.49M-$-4.94M
Total assets$16.1M$21.6M$25.5M$30.4M$36.3M
Total debt$200K$230K$170K$220K$260K
Net debt-$-1.04M-$-1.04M-$-740K-$-12.14M-$-28.83M
Total equity$14M$18.9M$23.4M$28.2M$34.8M
Cash and short-term investments$15.2M$19.9M$23.8M$29.7M$35.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$210K$0.00$510K
Cost of revenue$40K$0.00$160K$0.00$390K
Gross profit-$-40K$0.00$50K$0.00$130K
Research and development expenses$5.07M$6.4M$4.77M$6.7M$6.19M
Selling, general and administrative expenses$6.63M$7.43M$6.29M$7.17M$7.07M
Other expenses-$-40K$0.00$0.00$0.00$0.00
Operating expenses$11.7M$13.8M$11.1M$13.9M$13.3M
Cost and expenses$11.7M$13.8M$11.2M$13.9M$13.7M
Interest income$670K$1.13M$1.08M$100K$0.00
Interest expense$0.00$0.00$0.00$100K$0.00
Depreciation and amortization$40K$40K$50K$40K$60K
Ebitda-$-10.99M-$-12.66M-$-9.88M-$-13.73M-$-13.08M
Operating income-$-11.7M-$-13.83M-$-11.01M-$-13.88M-$-13.14M
Total other income/expenses, net$670K$1.13M$1.08M$100K$10K
Income before tax-$-11.03M-$-12.7M-$-9.93M-$-13.77M-$-13.13M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-10.93M-$-12.55M-$-9.81M-$-13.6M-$-12.95M
Weighted average shares outstanding$32.5M$31.9M$31M$30.4M$28.6M
Weighted average diluted shares outstanding$32.5M$31.9M$31M$30.4M$28.6M
Balance sheet
20252024202320222021
Cash and short-term investments$15.2M$19.9M$23.8M$29.7M$35.7M
Net receivables$0.00$170K$270K$50K$0.00
Inventory$0.00$0.00$0.00-$-50K$0.00
Total current assets$15.9M$21.4M$25.4M$30.2M$36M
Property, plant and equipment, net$190K$230K$170K$210K$250K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$190K$230K$170K$210K$250K
Total assets$16.1M$21.6M$25.5M$30.4M$36.3M
Accounts payable$170K$530K$210K$270K$140K
Short-term debt$40K$30K$50K$50K$40K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.97M$2.5M$2.03M$2.04M$1.27M
Long-term debt$160K$200K$120K$170K$220K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$160K$200K$120K$170K$220K
Capital lease obligations$160K$230K$170K$220K$260K
Total liabilities$2.13M$2.7M$2.15M$2.21M$1.49M
Common stock$330K$320K$310K$310K$300K
Retained earnings-$-251.68M-$-240.75M-$-228.2M-$-218.38M-$-204.79M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$14M$18.9M$23.4M$28.2M$34.8M
Total investments$13.9M$18.7M$22.9M$17.3M$6.6M
Total debt$200K$230K$170K$220K$260K
Net debt-$-1.04M-$-1.04M-$-740K-$-12.14M-$-28.83M
Cash flow statement
20252024202320222021
Net income-$-11.03M-$-12.7M-$-9.93M-$-13.77M-$-13.13M
Depreciation and amortization-$-110K$40K$50K$40K$60K
Stock-based compensation$3.68M$4.42M$4.42M$6M$7.5M
Change in working capital$150K$530K-$-1.06M$480K$80K
Accounts receivable$170K$100K-$-220K-$-30K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-360K$320K-$-60K$130K-$-100K
Net cash provided by operating activities-$-7.17M-$-7.33M-$-6.21M-$-6.49M-$-4.94M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$10K
Net cash used for investing activities$4.87M$4.28M-$-5.6M-$-10.73M-$-3.92M
Common stock issued$2.28M$2.96M$0.00$0.00$31.1M
Common stock repurchased$0.00-$-10K$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.28M$3.42M$370K$450K$31.6M
Net change in cash-$-30K$360K-$-11.45M-$-16.77M$22.7M
Cash at end of period$1.24M$1.27M$920K$12.4M$29.1M
Operating cash flow-$-7.17M-$-7.33M-$-6.21M-$-6.49M-$-4.94M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-7.17M-$-7.33M-$-6.21M-$-6.49M-$-4.94M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Anixa Biosciences, Inc.

        Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.

        CEO
        Amit Kumar
        Employees
        4
        Beta
        0.60

        Explore

        Frequently asked questions

        What is the intrinsic value of Anixa Biosciences, Inc. (ANIX)?

        InvestorsCraft does not currently publish an intrinsic value for ANIX. How the IC value is calculated.

        Is ANIX undervalued?

        InvestorsCraft does not publish an undervaluation signal for ANIX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.